Monthly Prescribing Reference

Keytruda Approved as Adjuvant Treatment for Stage IB, II, or IIIA NSCLC

The approval was based on data from the KEYNOTE-091 trial. The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab), as a single agent, for adjuvant treatment following surgical ...
Nasdaq

Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

KEYTRUDA in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for patients with hormone receptor-negative and human ...
Monthly Prescribing Reference

Keytruda Approved for First-Line Treatment of Advanced HER2-Negative Gastric Cancer

Keytruda approved for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma. The Food and Drug Administration (FDA) has approved Keytruda ...